vs
Side-by-side financial comparison of Evercore Inc. (EVR) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Evercore Inc. is the larger business by last-quarter revenue ($1.3B vs $708.5M, roughly 1.8× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 15.7%, a 3.3% gap on every dollar of revenue. On growth, Evercore Inc. posted the faster year-over-year revenue change (32.4% vs 32.0%). Evercore Inc. produced more free cash flow last quarter ($798.6M vs $188.1M). Over the past eight quarters, Evercore Inc.'s revenue compounded faster (48.9% CAGR vs 17.7%).
Evercore Inc., formerly known as Evercore Partners, is a global independent investment banking advisory firm founded in 1995 by Roger Altman, David Offensend, and Austin Beutner. The firm has advised on over $4.7 trillion of merger, acquisition, and restructuring transactions since its founding.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
EVR vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $708.5M |
| Net Profit | $204.0M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | 24.2% | 21.6% |
| Net Margin | 15.7% | 19.1% |
| Revenue YoY | 32.4% | 32.0% |
| Net Profit YoY | 45.2% | 15.5% |
| EPS (diluted) | $4.80 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3B | $708.5M | ||
| Q3 25 | $1.0B | $659.9M | ||
| Q2 25 | $838.0M | $603.3M | ||
| Q1 25 | $699.0M | $558.6M | ||
| Q4 24 | $979.5M | $536.6M | ||
| Q3 24 | $738.4M | $533.3M | ||
| Q2 24 | $693.4M | $528.1M | ||
| Q1 24 | $585.0M | $511.0M |
| Q4 25 | $204.0M | $135.1M | ||
| Q3 25 | $144.6M | $111.1M | ||
| Q2 25 | $97.2M | $90.3M | ||
| Q1 25 | $146.2M | $114.6M | ||
| Q4 24 | $140.4M | $117.0M | ||
| Q3 24 | $78.4M | $96.4M | ||
| Q2 24 | $73.8M | $88.4M | ||
| Q1 24 | $85.7M | $102.6M |
| Q4 25 | 24.2% | 21.6% | ||
| Q3 25 | 20.8% | 21.5% | ||
| Q2 25 | 18.0% | 20.9% | ||
| Q1 25 | 16.0% | 20.3% | ||
| Q4 24 | 21.8% | 23.4% | ||
| Q3 24 | 16.7% | 21.1% | ||
| Q2 24 | 15.9% | 19.9% | ||
| Q1 24 | 14.8% | 20.4% |
| Q4 25 | 15.7% | 19.1% | ||
| Q3 25 | 13.8% | 16.8% | ||
| Q2 25 | 11.6% | 15.0% | ||
| Q1 25 | 20.9% | 20.5% | ||
| Q4 24 | 14.3% | 21.8% | ||
| Q3 24 | 10.6% | 18.1% | ||
| Q2 24 | 10.6% | 16.7% | ||
| Q1 24 | 14.6% | 20.1% |
| Q4 25 | $4.80 | $4.65 | ||
| Q3 25 | $3.41 | $3.86 | ||
| Q2 25 | $2.36 | $3.10 | ||
| Q1 25 | $3.48 | $3.67 | ||
| Q4 24 | $3.32 | $3.67 | ||
| Q3 24 | $1.86 | $3.01 | ||
| Q2 24 | $1.81 | $2.75 | ||
| Q1 24 | $2.09 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0B | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.0B | $459.1M |
| Total Assets | $5.4B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0B | $497.0M | ||
| Q3 25 | $2.4B | $285.4M | ||
| Q2 25 | $1.7B | $46.3M | ||
| Q1 25 | $1.4B | $441.4M | ||
| Q4 24 | $2.4B | $669.4M | ||
| Q3 24 | $1.8B | $656.9M | ||
| Q2 24 | $1.7B | $510.9M | ||
| Q1 24 | $1.4B | $407.0M |
| Q4 25 | $2.0B | $459.1M | ||
| Q3 25 | $1.8B | $293.6M | ||
| Q2 25 | $1.7B | $172.4M | ||
| Q1 25 | $1.5B | $593.6M | ||
| Q4 24 | $1.7B | $825.5M | ||
| Q3 24 | $1.6B | $881.4M | ||
| Q2 24 | $1.5B | $763.6M | ||
| Q1 24 | $1.4B | $671.5M |
| Q4 25 | $5.4B | $2.0B | ||
| Q3 25 | $4.4B | $1.8B | ||
| Q2 25 | $3.7B | $1.6B | ||
| Q1 25 | $3.3B | $1.9B | ||
| Q4 24 | $4.2B | $2.1B | ||
| Q3 24 | $3.6B | $2.1B | ||
| Q2 24 | $3.3B | $1.9B | ||
| Q1 24 | $3.0B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $807.5M | $192.7M |
| Free Cash FlowOCF − Capex | $798.6M | $188.1M |
| FCF MarginFCF / Revenue | 61.6% | 26.6% |
| Capex IntensityCapex / Revenue | 0.7% | 0.6% |
| Cash ConversionOCF / Net Profit | 3.96× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $1.2B | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $807.5M | $192.7M | ||
| Q3 25 | $560.9M | $246.2M | ||
| Q2 25 | $437.7M | $148.5M | ||
| Q1 25 | $-549.7M | $125.8M | ||
| Q4 24 | $686.4M | $190.7M | ||
| Q3 24 | $234.5M | $149.1M | ||
| Q2 24 | $348.5M | $116.4M | ||
| Q1 24 | $-281.2M | $152.7M |
| Q4 25 | $798.6M | $188.1M | ||
| Q3 25 | $541.5M | $235.5M | ||
| Q2 25 | $411.7M | $142.4M | ||
| Q1 25 | $-569.3M | $115.8M | ||
| Q4 24 | $673.1M | $183.0M | ||
| Q3 24 | $226.6M | $138.5M | ||
| Q2 24 | $340.7M | $103.5M | ||
| Q1 24 | $-282.3M | $147.2M |
| Q4 25 | 61.6% | 26.6% | ||
| Q3 25 | 51.8% | 35.7% | ||
| Q2 25 | 49.1% | 23.6% | ||
| Q1 25 | -81.4% | 20.7% | ||
| Q4 24 | 68.7% | 34.1% | ||
| Q3 24 | 30.7% | 26.0% | ||
| Q2 24 | 49.1% | 19.6% | ||
| Q1 24 | -48.3% | 28.8% |
| Q4 25 | 0.7% | 0.6% | ||
| Q3 25 | 1.9% | 1.6% | ||
| Q2 25 | 3.1% | 1.0% | ||
| Q1 25 | 2.8% | 1.8% | ||
| Q4 24 | 1.4% | 1.4% | ||
| Q3 24 | 1.1% | 2.0% | ||
| Q2 24 | 1.1% | 2.4% | ||
| Q1 24 | 0.2% | 1.1% |
| Q4 25 | 3.96× | 1.43× | ||
| Q3 25 | 3.88× | 2.22× | ||
| Q2 25 | 4.50× | 1.65× | ||
| Q1 25 | -3.76× | 1.10× | ||
| Q4 24 | 4.89× | 1.63× | ||
| Q3 24 | 2.99× | 1.55× | ||
| Q2 24 | 4.72× | 1.32× | ||
| Q1 24 | -3.28× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EVR
| Advisory Fees | $1.1B | 87% |
| Commissions And Related Revenue | $66.5M | 5% |
| Underwriting Fees | $49.5M | 4% |
| Other | $29.6M | 2% |
| Investment Management | $23.2M | 2% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
